[go: up one dir, main page]

WO2001069260A3 - Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein - Google Patents

Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein Download PDF

Info

Publication number
WO2001069260A3
WO2001069260A3 PCT/US2001/007393 US0107393W WO0169260A3 WO 2001069260 A3 WO2001069260 A3 WO 2001069260A3 US 0107393 W US0107393 W US 0107393W WO 0169260 A3 WO0169260 A3 WO 0169260A3
Authority
WO
WIPO (PCT)
Prior art keywords
cln2p
breast cancer
breast
activity
primary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007393
Other languages
English (en)
Other versions
WO2001069260A2 (fr
Inventor
Raju K Pullarkat
Mohammad A Junaid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Mental Hygiene Inc
Original Assignee
Research Foundation for Mental Hygiene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Mental Hygiene Inc filed Critical Research Foundation for Mental Hygiene Inc
Priority to JP2001568088A priority Critical patent/JP2003527607A/ja
Priority to AU2001247317A priority patent/AU2001247317A1/en
Priority to CA002403373A priority patent/CA2403373A1/fr
Priority to US10/221,565 priority patent/US20030211554A1/en
Priority to EP01920239A priority patent/EP1269193A2/fr
Publication of WO2001069260A2 publication Critical patent/WO2001069260A2/fr
Publication of WO2001069260A3 publication Critical patent/WO2001069260A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

L'invention concerne des techniques diagnostiques et pronostiques permettant de détecter dans des échantillons vasculaires et de tissu la présence et l'activité de la protéinase lysosomiale insensible à la pepstatine, CLN2p, qui a été récemment associée au cancer du sein et constitue un nouveau biomarqueur du cancer du sein, y compris tumeurs du sein primaires, non primaires ou métastatiques, néoplasmes et carcinomes. L'activité mesurée de CLN2p est considérablement élevée dans les échantillons de tissu de sein qui proviennent de patientes présentant un carcinome du sein, par comparaison avec les taux de CLN2p d'échantillons témoins normaux ; cette activité de CLN2p est d'approximativement deux à dix-sept fois supérieure en présence de tumeurs du sein. Les taux supérieurs d'activité de CLN2p dans les tumeurs du sein ont été corrélés avec succès à plusieurs biomarqueurs de cancer du sein connus, tels que la cathepsine D, le récepteur des oestrogènes et le récepteur de la progestérone. L'invention concerne CLN2p comme nouveau biomarqueur utile dans la détection, le diagnostic et le pronostic du cancer du sein.
PCT/US2001/007393 2000-03-13 2001-03-08 Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein Ceased WO2001069260A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001568088A JP2003527607A (ja) 2000-03-13 2001-03-08 乳癌の検出および診断のための新規バイオマーカーとしてのリソソームペプスタチン非感受性タンパク質分解酵素
AU2001247317A AU2001247317A1 (en) 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
CA002403373A CA2403373A1 (fr) 2000-03-13 2001-03-08 Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein
US10/221,565 US20030211554A1 (en) 2001-03-08 2001-03-08 Lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
EP01920239A EP1269193A2 (fr) 2000-03-13 2001-03-08 Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18886100P 2000-03-13 2000-03-13
US60/188,861 2000-03-13

Publications (2)

Publication Number Publication Date
WO2001069260A2 WO2001069260A2 (fr) 2001-09-20
WO2001069260A3 true WO2001069260A3 (fr) 2002-05-10

Family

ID=22694851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007393 Ceased WO2001069260A2 (fr) 2000-03-13 2001-03-08 Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein

Country Status (5)

Country Link
EP (1) EP1269193A2 (fr)
JP (1) JP2003527607A (fr)
AU (1) AU2001247317A1 (fr)
CA (1) CA2403373A1 (fr)
WO (1) WO2001069260A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089073A2 (fr) * 2003-04-03 2004-10-21 Genpath Pharmaceuticals, Incorporated Modele inductible pour cancer du sein
WO2007088971A1 (fr) * 2006-02-03 2007-08-09 Messengerscape Co., Ltd. Groupe de genes applicable au pronostic d'un cancer
CA2644343A1 (fr) * 2006-03-17 2007-09-27 Biomarin Pharmaceutical Inc. Dosages pour la detection d'anticorps anti enzymes lysosomales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024065A1 (fr) * 1995-02-03 1996-08-08 Oncogene Science, Inc. Procedes de detection de procathepsines et leurs emplois
WO1998055872A1 (fr) * 1997-06-03 1998-12-10 Amdl, Inc. Analyse immunologique pour la detection du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024065A1 (fr) * 1995-02-03 1996-08-08 Oncogene Science, Inc. Procedes de detection de procathepsines et leurs emplois
WO1998055872A1 (fr) * 1997-06-03 1998-12-10 Amdl, Inc. Analyse immunologique pour la detection du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNAID M A ET AL: "A lysosomal pepstatin-insensitive proteinase as anovel biomarker for breast carcinoma", THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 15, no. 2, 2000, pages 129 - 134, XP008001480 *

Also Published As

Publication number Publication date
AU2001247317A1 (en) 2001-09-24
WO2001069260A2 (fr) 2001-09-20
CA2403373A1 (fr) 2001-09-20
EP1269193A2 (fr) 2003-01-02
JP2003527607A (ja) 2003-09-16

Similar Documents

Publication Publication Date Title
Yang et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer
Leygo et al. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer
Urakami et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection
Sanguedolce et al. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review
Leja et al. Early detection of gastric cancer beyond endoscopy-new methods
WO2006089212A3 (fr) Cyr61 comme biomarqueur pour le diagnostic et le pronostic de cancers d'origine epitheliale
EP1804062A3 (fr) YKL-40 en tant que marqueur et indicateur de pronostic de cancers
Yamamoto et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less
WO2002035232A3 (fr) Methode de detection ddu cancer de l'ovaire
CA2384579A1 (fr) Marqueur de tumeur pour les cancers a un stade precoce
WO2002037112A3 (fr) Detection du cancer de l'ovaire
Adams et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma
Zaorsky et al. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?
Mueller et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients
Hung et al. Evaluating the prediction of breast cancer survival using lymph node ratio
Lin et al. Aberrant promoter methylation of PCDH17 (Protocadherin 17) in serum and its clinical significance in renal cell carcinoma
WO2007056523A3 (fr) Procedes de diagnostic et de surveillance de la progression d'un cancer
WO2002064015A8 (fr) Pin1 utilise comme marqueur pour le cancer de la prostate
Lamb et al. Prostate cancer: the new evidence base for diagnosis and treatment
WO2001069260A3 (fr) Proteinase lysosomiale insensible a la pepstatine comme nouveau biomarqueur pour detecter et diagnostiquer le cancer du sein
WO2012145399A2 (fr) Procédés de diagnostic d'un cancer chez un patient
Botelho et al. Does baseline total testosterone improve the yielding of prostate cancer screening?
Bangma et al. Free and total prostate‐specific antigen in a screened population
Pappas et al. Early detection and staging of adenocarcinoma of the pancreas
Scarlett et al. Classification of pancreatic cystic lesions using SELDI‐TOF mass spectrometry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 568088

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001247317

Country of ref document: AU

Ref document number: 2403373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001920239

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221565

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001920239

Country of ref document: EP